[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometriosis-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometriosis-diagnosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,72,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100636066","impact-of-endotest-on-patients-quality-of-life-a-cohort-study-100636066",false,"NCT07560852","Impact of Endotest on Patients' Quality of Life: a Cohort Study","ENDOLIFE","Inclusion Criteria:\n\n* Women with a prescription for Endotest\n* Women aged 18 to 43\n* Who have dated and signed the consent form\n* Affiliated with the French healthcare system or covered by health insurance abroad\n\nExclusion Criteria:\n\n* Contraindications for the use of Endotest:\n\n  1. Current pregnancy;\n  2. Medical history of cancer or HIV infection;\n  3. Active infection at the time of saliva collection;\n* Significant difficulty reading and understanding the language of the country in which the participant is located.","FEMALE","18 Years","43 Years",{"count":20,"type":21},20000,"ESTIMATED","16 Months","OBSERVATIONAL","Ziwig Endotest® ('Endotest') is marketed in several countries, including Switzerland, which was the first country to make it available in 2022. Since February 2025, several French clinical investigation sites have been offering Endotest, developed by Ziwig, under the innovation funding. Initially, this innovation funding enabled 2,500 patients to be included in a clinical trial (ENDOBEST: ID-RCB 2024-A02092-45). Since the end of December 2025, it has been expanded and now covers a further 22,500 patients whose are not included in the trial. This medical device is based on Next-Generation Sequencing combined with analytical algorithms and enables the identification of endometriosis from a saliva sample. This non-invasive test aims to improve patient care by reducing diagnostic delays and guiding treatment strategies.\n\nDespite the available data on its diagnostic performance, the impact of Endotest on patients' quality of life, their emotional experience, their coping strategies, and their care pathways remains insufficiently documented. Indeed, the Endotest result (positive or negative) can significantly influence these various aspects. This cohort study aims to assess the impact of Endotest on patients' quality of life, primarily using validated self-report questionnaires and clinical data from medical records. By including a large sample of patients, this study aims to provide robust and generalisable data that will be useful for clinicians and patients themselves.",[26,27],"Patient With a Prescribed Endotest","Endometriosis (Diagnosis)",[29],"endometriosis","RECRUITING","2026-05-20",{"date":33,"type":34},"2026-05-26","ACTUAL",{"date":36,"type":34},"2026-05-06",{"date":38,"type":21},"2029-07-31",{"name":40,"class":41},"ZIWIG","INDUSTRY",7,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100623232","impact-of-food-supplementation-on-quality-of-life-in-patients-with-endometriosis-and-pelvic-pain-100623232","NCT07393958","Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain.","Experimental Study of Quality of Life in Patients With Endometriosis and Pelvic Pain Treated With Doliral Dietary Supplementation Versus Placebo.","ENDOLIRAL","Inclusion Criteria:\n\n* Women of reproductive age with diagnosed endometriosis stage I, II, or III, according to the American Society for Reproductive Medicine (ASRM) classification.\n* Women with a diagnosis of endometriosis confirmed by laparoscopy or, in the absence of laparoscopy, by magnetic resonance imaging (MRI) and\u002For ultrasound.\n* Presence of pelvic pain (VAS \\> 4) during the last three months.\n* No indication for surgical intervention at the time of inclusion in the study.\n* Patients who are able to provide informed consent.\n\nExclusion Criteria:\n\n* Patients under 18 years of age.\n* Use of analgesic or anti-inflammatory pharmacological treatment, except for ibuprofen at doses up to 600 mg\u002Fday or naproxen at doses up to 500 mg\u002Fday.\n* Surgery within the year prior to inclusion, performed for therapeutic purposes related to the pathology under study.\n* Initiation or discontinuation of hormone therapy within the three months prior to inclusion in the study.\n* Patients with known allergy or hypersensitivity to Doliral®.\n* Pregnant or breastfeeding patients.\n* Patients on sick leave: \\> 1 year, or With no intention of returning to work, or Undergoing a disability or permanent incapacity assessment process.",{"count":52,"type":21},60,"INTERVENTIONAL",[55],"NA","This study examines whether the food supplement Doliral can improve quality of life and reduce pelvic pain in women with endometriosis, compared with placebo, over several weeks.",[27],[59,60,61],"pain","QoL","food supplement","2026-02-27",{"date":64,"type":34},"2026-03-02",{"date":66,"type":34},"2026-02-26",{"date":68,"type":21},"2026-09-15",{"name":70,"class":41},"Arafarma Group, S.A.",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":5},"100625839","observational-study-on-the-use-of-ultrasound-to-recognize-superficial-endometriosis-in-a-specific-area-of-the-pelvis-the-uterosacral-ligaments-100625839","NCT07427849","Observational Study on the Use of Ultrasound to Recognize Superficial Endometriosis in a Specific Area of the Pelvis (the Uterosacral Ligaments)","Ultrasound Diagnosis of Superficial Endometriosis of LUS (Uterosacral Ligaments): Definition of a Laparoscopically Validated Ultrasound Cut-off.","LUS","Inclusion Criteria:\n\n* patients who need to undergo gynecological surgery with a laparoscopic approach for benign pathology (endometriosis, uterine fibroids, adenomyosis, chronic pelvic pain, benign ovarian cysts) or non-advanced malignant pathology (stage I endometrium and cervix, stage I and II ovary).\n* patients who performed a level II gynecological ultrasound with an experienced operator in the preoperative pathway.\n* technical possibility of performing a transvaginal ultrasound and the patient's willingness to undergo such an investigation.\n* patients of childbearing age (18 - 50 years).\n* Signing of informed consent.\n\nExclusion Criteria:\n\n* presence of endometriosis deeply infiltrating the posterior compartment. This may interfere with the interpretation of uterosacral ligament (LUS) thickness as a specific marker of superficial endometriosis\n* technical impossibility of performing a transvaginal ultrasound (patient virgo, patient refusal).\n* incomplete ultrasound evaluation of the uterosacral ligaments for anatomical reasons or for the presence of endometriosis nodules from other sites with partial involvement of the LUS (uterosacral ligament).\n* advanced malignant disease (\\>Stage I for endometrium and cervix, \\> Stage II for ovary)\n* pelvic organ prolapse\n* PID or other pelvic inflammatory diseases\n* medical emergencies (ovarian torsion, hemoperitoneum)\n* postmenopausal patients\n* previous pelvic surgery","50 Years",{"count":82,"type":21},64,"An observational, prospective, multicenter study conducted on patients of childbearing age undergoing laparoscopic surgery for early-stage benign or malignant gynecological disease. The study does not include changes to the standard care pathway.",[27],[86,87,88,89],"ultrasound","gynecology","laparoscopic surgery","uterosacral ligaments","2026-02-23",{"date":92,"type":34},"2026-02-25",{"date":94,"type":34},"2026-02-17",{"date":96,"type":21},"2026-08",{"name":98,"class":99},"Casa di Cura Dott. Pederzoli","OTHER",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":53,"phases":109,"briefSummary":111,"conditions":112,"keywords":121,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":71},"100604083","phase-4-assessing-the-efficacy-of-indocyanine-green-for-ureter-identification-during-robot-assisted-surgery-in-advanced-stage-endometriosis-100604083","NCT07144904","Assessing the Efficacy of Indocyanine Green for Ureter Identification During Robot-Assisted Surgery in Advanced-Stage Endometriosis","A Side-Randomized, Self-Controlled Trial Assessing the Efficacy of Indocyanine Green Fluorescence Imaging for Intraoperative Ureter Identification During Robot-Assisted Single-Site Surgery in Advanced-Stage Endometriosis","Inclusion Criteria:\n\n* Stage III or IV endometriosis (rASRM classification)\n* Planned robotic transabdominal endometriosis excision with or without hysterectomy.\n\nExclusion Criteria:\n\n\\- Subjects who are part of a vulnerable population will be excluded including those who are prisoners, younger than 18 years old, pregnant, individuals with mental disabilities or cognitive impairment.",{"count":108,"type":21},40,[110],"PHASE4","The goal of this side-randomized, self-controlled trial, 1-site study is to explore the efficacy of Indocyanine Green Fluorescence (ICG) for Intraoperative Ureter Identification During Robot-Assisted Single-Site Surgery in Advanced-Stage Endometriosis.\n\nResearchers will perform temporary ureteral stent using indocyanine green fluorescence for intraoperative ureteral identification on either the left or right side of subjects who are undergoing a robotic assisted transumbilical resection of advanced endometriosis.\n\nParticipants will be randomized to receive ICG-assisted ureteral identification on either the left or right side. Randomization will be conducted using a computer-generated block randomization method.\n\nThe primary aim is to determine whether ICG-assisted ureter visualization can reduce operative time for endometriosis resection and ureterolysis, and minimize the risk of ureteral injury.\n\nSecondary objectives are to assess the feasibility and safety of temporary ureteral ICG stenting for intraoperative ureter identification in advanced endometriosis.",[113,114,115,116,27,117,118,119,120],"Indocyanine Green (ICG)","Robotic Surgical Procedure","Deep Infiltrating Endometriosis (DIE)","Endometriosis Pelvic","Endometriosis of the Cul-de-sac","Ureteral Stent Placement","Ureteral Injury","Endometriosis Ovaries",[122,123,29,124,125],"ureteral stent placement","indocyanine green","robotic surgery","ureteral identification","NOT_YET_RECRUITING","2025-08-20",{"date":129,"type":34},"2025-08-28",{"date":131,"type":21},"2025-10-01",{"date":133,"type":21},"2026-03-15",{"name":135,"class":99},"Baylor College of Medicine"]